Outcome of preoperative oral sildenafil in patients with pulmonary hypertension after mitral valve replacement.
DOI:
https://doi.org/10.29309/TPMJ/2021.28.02.6250Keywords:
Left Ventricular Ejection Fraction, Mitral Valve Replacement, Mitral Valve Disease, Pulmonary Hypertension, Right Ventricular Failure, SildenafilAbstract
Objective: To determine the role of preoperative administration of sildenafil on pulmonary hypertension in patients with mitral valve disease undergoing mitral valve replacement surgery. Study Design: Randomized Control Trial. Setting: Department of Cardiac Surgery, Faisalabad Institute of Cardiology, Faisalabad. Period: June 2018 to June 2020. Material & Methods: A total of 310 patients with mitral valve disease who underwent mitral valve replacement were included. The patients were divided into a control group of 155, who were not administered oral sildenafil, and a study group of 155 who received oral sildenafil preoperatively. TVPG, LVEF and NYHA class were recorded preoperatively and postoperatively and were compared. Results: In the study group, postoperative LVEFs and NYHA class were not statistically significant in both groups while postoperative TVPG was significantly lower in study group as compare to control group and is statistically significant (P<0.001). Conclusion: Our study concludes that oral sildenafil preoperatively can be used as an effective therapy to reduce pulmonary pressure in patients with pulmonary hypertension undergoing mitral valve replacement surgery.